非酒精性脂肪性肝病的治疗研究进展  

Research progress on the treatment of non-alcoholic fatty liver disease

作　　者：齐静 高杉杉 张帆 赵子恒 李坤[2] QI Jing;GAO Shanshan;ZHANG Fan;ZHAO Ziheng;LI Kun(School of Clinical Medicine(Affiliated Hospital),Jining Medical University,Jining 272002,China;不详)

机构地区：[1]济宁医学院临床医学院(附属医院),山东济宁272002 [2]山东第一医科大学第一附属医院(山东省千佛山医院)消化内科,山东济南250000

出　　处：《山东医药》2025年第3期139-143,共5页Shandong Medical Journal

摘　　要：非酒精性脂肪性肝病(NAFLD)是全球最常见的肝脏疾病,也称代谢相关脂肪性肝病(MAFLD)。全球范围内NAFLD发病率正在逐年升高,治疗不及时可能会逐渐进展为肝炎、肝纤维化、肝硬化。但目前我国未有正式批准上市的NAFLD治疗药物,所以针对该病的治疗逐渐成为热点。目前,全球针对NAFLD的治疗研究包括但不限于饮食及生活方式干预、维生素E、他汀类降脂药、胰高血糖素样肽1(GLP-1)受体激动剂、钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂、过氧化物酶体增殖物激活受体(PPAR)激动剂、乙酰辅酶A羧化酶(ACC)抑制剂、糖聚乙二醇化成纤维细胞生长因子19(FGF19)/FGF21类似物、法尼醇X受体激动剂、益生菌、甲状腺激素受体β(THR-β)激动剂等。2024年3月,具有高度选择性和口服活性的THR-β激动剂Resmetirom获得美国食品和药物管理局批准上市,与饮食控制和运动联合用于中期至晚期肝纤维化的非酒精性脂肪性肝炎成人患者的治疗,虽然Resmetirom未在中国上市,但也为NAFLD的治疗提供了希望。Non-alcoholic fatty liver disease(NAFLD)is the most common liver disease worldwide,now renamed as metabolism-associated fatty liver disease(MAFLD).The incidence of NAFLD is increasing year by year worldwide,and delayed treatment may gradually progress to hepatitis,liver fibrosis,and cirrhosis.However,there are no officially approved drugs on the market in China,so therapeutic drugs for this disease have become a hot issue.Current global therapeutic studies for NAFLD include,but are not limited to,dietary and lifestyle interventions,vitamin E,statin lipid-lowering drugs,GLP-1 receptor agonists,SGLT2 inhibitors,PPAR agonists,ACC inhibitors,FGF19/21 inhibitors,farnesol X receptor agonists,probiotics,and thyroid β agonists,etc.In March,2024,Resmetirom was approved for marketing by the U.S.Food and Drug Administration(FDA)for the treatment of adult patients with non-alcoholic hepatitis with intermediate to advanced liver fibrosis in combination with diet and exercise.Although Resmetirom is not available in China,it provides hope for the treatment of this disease.

关 键 词：非酒精性脂肪性肝病 非酒精性脂肪性肝炎 维生素E 降脂药物 

分 类 号：R575.5[医药卫生—消化系统]